{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:23:41Z","timestamp":1783635821974,"version":"3.55.0"},"publisher-location":"New York, NY","reference-count":10,"publisher":"Springer US","isbn-type":[{"value":"9781071650493","type":"print"},{"value":"9781071650509","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-1-0716-5050-9_9","type":"book-chapter","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:06:47Z","timestamp":1783634807000},"page":"99-109","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Androgen Receptor Splice Variant-7 Expression Analysis in Circulating Tumor Cells: Methodology and Application of AdnaTest in Prostate Cancer Research"],"prefix":"10.1007","author":[{"given":"Naoya","family":"Nagaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Horie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"issue":"11","key":"9_CR1","doi-asserted-by":"publisher","first-page":"18550","DOI":"10.18632\/oncotarget.14537","volume":"8","author":"KM Wadosky","year":"2017","unstructured":"Wadosky KM, Koochekpour S (2017) Androgen receptor splice variants and prostate cancer: from bench to bedside. Oncotarget 8(11):18550\u201318576. https:\/\/doi.org\/10.18632\/oncotarget.14537","journal-title":"Oncotarget"},{"issue":"11","key":"9_CR2","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis ES, Lu C, Wang H, Luber BS, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng\u00a0Q, De\u00a0Marzo AM, Isaacs JT, Isaacs WB, Nadal\u00a0R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371(11):1028\u20131038","journal-title":"N Engl J Med"},{"issue":"19","key":"9_CR3","doi-asserted-by":"publisher","first-page":"e15608","DOI":"10.1097\/md.0000000000015608","volume":"98","author":"A Sciarra","year":"2019","unstructured":"Sciarra A, Gentilucci A, Silvestri I, Salciccia S, Cattarino S, Scarpa S, Gatto A, Frantellizzi V, Von Heland M, Ricciuti GP, Del Giudice F, Maggi M (2019) Androgen receptor variant 7 (AR-V7) in sequencing therapeutic agents for castratrion resistant prostate cancer: a critical review. Medicines (Baltimore) 98(19):e15608. https:\/\/doi.org\/10.1097\/md.0000000000015608","journal-title":"Medicines (Baltimore)"},{"key":"9_CR4","doi-asserted-by":"publisher","unstructured":"Nimir M, Ma Y, Jeffreys SA, Opperman T, Young F, Khan T, Ding P, Chua W, Balakrishnar B, Cooper A, De Souza P, Becker TM (2019) Detection of AR-V7 in liquid biopsies of castrate resistant prostate cancer patients: a comparison of AR-V7 analysis in circulating tumor cells, circulating tumor RNA and exosomes. Cells 8(7):688. https:\/\/doi.org\/10.3390\/cells8070688","DOI":"10.3390\/cells8070688"},{"key":"9_CR5","doi-asserted-by":"publisher","unstructured":"Armstrong AJ, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, Danila DC, Healy P, Anand M, Berry WR, Zhang T, Harrison MR, Lu C, Chen Y, Galletti G, Schonhoft JD, Scher HI, Wenstrup R, Tagawa ST, Antonarakis ES, George DJ, Halabi S (2020) Prospective multicenter study of circulating tumor cell AR-V7 and taxane versus hormonal treatment outcomes in metastatic castration-resistant prostate cancer. JCO Precis Oncol 4:PO.20.00200. https:\/\/doi.org\/10.1200\/po.20.00200","DOI":"10.1200\/po.20.00200"},{"issue":"5","key":"9_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/ppo.0000000000000220","volume":"22","author":"DC Danila","year":"2016","unstructured":"Danila DC, Samoila A, Patel C, Schreiber N, Herkal A, Anand A, Bastos D, Heller G, Fleisher M, Scher HI (2016) Clinical validity of detecting circulating tumor cells by AdnaTestassay compared with direct detection of tumor mRNA instabilized whole blood, as a biomarker predicting overall survival for metastatic castration-resistant prostate cancer patients. Cancer J 22(5):315\u2013320. https:\/\/doi.org\/10.1097\/ppo.0000000000000220","journal-title":"Cancer J"},{"key":"9_CR7","doi-asserted-by":"publisher","unstructured":"Sobhani N, Neeli PK, D\u2019Angelo A, Pittacolo M, Sirico M, Galli IC, Roviello G, Nesi G (2021) AR-V7 in metastatic prostate cancer: a strategy beyond redemption. Int J Mol Sci 22(11):5515. https:\/\/doi.org\/10.3390\/ijms22115515","DOI":"10.3390\/ijms22115515"},{"issue":"1","key":"9_CR8","doi-asserted-by":"publisher","first-page":"18016","DOI":"10.1038\/s41598-022-22854-1","volume":"12","author":"T Ashizawa","year":"2022","unstructured":"Ashizawa T, Nagata M, Nakamura S, Hirano H, Nagaya N, Lu Y, Horie S (2022) Efficacy of cabazitaxel and androgen splicing variant-7 status in circulating tumor cells in Asian patients with metastatic castration-resistant prostate cancer. Sci Rep 12(1):18016. https:\/\/doi.org\/10.1038\/s41598-022-22854-1","journal-title":"Sci Rep"},{"issue":"1","key":"9_CR9","doi-asserted-by":"publisher","first-page":"8704","DOI":"10.1038\/s41598-023-35790-5","volume":"13","author":"H Hirano","year":"2023","unstructured":"Hirano H, Nagata M, Nagaya N, Nakamura S, Ashizawa T, Lu Y, Kawano H, Kitamura K, Sakamoto Y, Fujita K, Isobe H, Tsujimura A, Muto S, Horie S (2023) Bone scan index (BSI) scoring by using bone scintigraphy and circulating tumor cells (CTCs): predictive factors for enzalutamide effectiveness in patients with castration-resistant prostate cancer and bone metastases. Sci Rep 13(1):8704. https:\/\/doi.org\/10.1038\/s41598-023-35790-5","journal-title":"Sci Rep"},{"key":"9_CR10","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3389\/fonc.2020.00495","volume":"10","author":"N Nagaya","year":"2020","unstructured":"Nagaya N, Kanayama M, Nagata M, Horie S (2020) Abiraterone rechallenge based on sequential testing of androgen receptor splice variant 7 expression in circulating tumor cells: a case report. Front Oncol 10:495. https:\/\/doi.org\/10.3389\/fonc.2020.00495","journal-title":"Front Oncol"}],"container-title":["Methods in Molecular Biology","Circulating Tumor Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-5050-9_9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:06:47Z","timestamp":1783634807000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-5050-9_9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9781071650493","9781071650509"],"references-count":10,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-5050-9_9","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"3 June 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}